Publications by authors named "I A Lehtinen"

Background/aim: New fractionation schedules with modern tools are a very rapidly developing area in curative radiotherapy (RT) for early prostate cancer (PC). To apply these techniques in everyday clinical practice, we planned this phase II trial with different fractionation schedules and followed up patients using careful health-related quality of life (QoL) questionnaires for three years.

Patients And Methods: Seventy-three PC patients with one or two intermediate PC risk factors according to the National Comprehensive Cancer Network criteria were recruited.

View Article and Find Full Text PDF

Background: The effects of radiotherapy (RT) patients' health-related quality of life (HRQoL) are usually compared to those of other treatment modalities instead of HRQoL of the general population in oncological studies. We examined HRQoL of patients with an early prostate cancer (PC) not receiving hormonal treatment up to 3 years after RT using the 15D instrument and the FACT-P questionnaire.

Methods: The 15D results were compared to those in the age-standardized general male population (N = 952) using an independent-sample t test.

View Article and Find Full Text PDF

Introduction: Treatment with 2-weekly docetaxel 50 mg/m was shown to improve overall survival and was better tolerated than the standard 75 mg/m 3-weekly regimen in men with metastatic castration-resistant prostate cancer (mCRPC) in the original randomised PROSTY trial. The aim of this study was to investigate, whether quality of life (QoL) effects would differ between the 2-weekly docetaxel 50 mg/m regimen from the standard 3-weekly 75 mg/m treatment.

Materials And Methods: QoL data were collected with the Functional Assessment of Cancer Therapy - Prostate (FACT-P) and Functional Assessment of Cancer Therapy Advanced Prostate Symptom Index - 8 Item version (FAPSI-8).

View Article and Find Full Text PDF

Background: Identification of genetic prognostic biomarkers, such as germline variants, are urgently needed to choose optimal treatment for metastatic castration-resistant prostate cancer (mCRPC).

Patients And Methods: The prognostic value of anoctamin 7 (ANO7) rs77559646 on docetaxel response was tested in a prospective PROSTY randomized trial and a retrospective Auria Biobank set. The variant rs77559646 was genotyped and its association with progression-free survival (PFS) and overall survival (OS) was tested.

View Article and Find Full Text PDF

Despite several fungal strains have been retrieved from methane-containing environments, the actual capacity and role of fungi on methane abatement is still unclear. The batch biodegradation tests here performed demonstrated the capacity of Graphium sp. to co-metabolically biodegrade methane and methanol.

View Article and Find Full Text PDF